The Medical Letter on Drugs and Therapeutics
Capsaicin Patch (Qutenza) for Postherpetic Neuralgia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a topical 8% patch formulation of capsaicin (Qutenza – NeurogesX), available only by prescription, for local treatment of postherpetic neuralgia. Postherpetic neuralgia occurs after herpes zoster in about one third of patients ≥60 years old and can persist for months or even years.1

STANDARD TREATMENT — Opioids and topical analgesics such as lidocaine (Lidoderm) are commonly used to treat postherpetic neuralgia. Oral nonopioid analgesics generally have not been effective for this indication. The anticonvulsants pregabalin (Lyrica) and gabapentin (Neurontin, and others) are FDA-approved for treatment of postherpetic neuralgia.2 Tricyclic antidepressants have been used as an adjunct, but their use has been limited by anticholinergic side effects. Lower-strength (0.025%-0.15%) cream, liquid ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Capsaicin Patch (Qutenza) for Postherpetic Neuralgia
Article code: 1365c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian